- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01916577
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators have developed a new therapy utilizing a stem cell found in the bone marrow that is defined by cell surface expression of the protein "cluster of differentiation antigen 117" (CD117). Studies utilizing these stem cells in a mouse heart transplant model have demonstrated significantly improved survival of transplanted hearts, (as much as more than 5 times that seen with untreated heart transplants). In vitro studies in mice also show that these cells work to inhibit the immune system by inhibiting T cell activation/proliferation by both paracrine (primary) and contact-dependent (lesser) mechanisms. Importantly, these stem cells are taken from the intended transplant recipient (autologous) and since these cells are part of their own body normally (in small numbers); these cells are theoretically without risk to the patient. This is very different from other stem cell therapies, which are taken from the donor and as such put the patient at significant risk of developing potentially life-threatening immune reactions. Because the use of our own stem cells is potentially safe - the rapid study, development, and implementation of autologous CD117 stem cell (SC) therapy in human transplant patients is theoretically possible. Therefore, these cells have high impact potential for the field of tissue and organ transplantation as well as auto-immunity - to potentially improve tissue/cellular engraftment, decrease acute rejection, and/or to promote organ transplant tolerance (lack of rejection despite no concomitant immune-suppression). Prior to full clinical development (efficacy trials in humans), the next step is to develop a safe and efficacious means for obtaining relatively large quantities of these cells from potential human recipients. As bone marrow biopsy for cell capture is not without risk (especially to ill potential lung transplant recipients), the investigators propose to use Plerixafor (Mozobil), a CXC-chemokine receptor 4 (CXCR4)-inhibitor to cause efflux of bone marrow-derived CD117+ cells to the peripheral blood for capture by apheresis/positive selection. If successful, the next step will be to perform initial safety studies in human patients awaiting transplantation and normal controls (not a goal of this initial protocol however). These studies have the potential to lead to large-scale clinical efficacy trials and ultimate indication/implementation for human disease(s).
Primary Outcome Measure: The number of circulating CD117+ cells per milliliter (ml) of peripheral blood at baseline and following Plerixafor (Mozobil) treatment (change in peripheral blood CD117+ cells per ml).
Secondary Outcome Measures:
i.) The number of Plerixafor (Mozobil) related adverse events (AEs). ii.) The number of patients with Plerixafor (Mozobil) related AEs iii.) The number of Plerixafor (Mozobil) related serious adverse events (SAEs). iv.) The number of patients with Plerixafor (Mozobil) related serious adverse events (SAEs).
As listed in the package insert, the most common adverse reactions (≥10%) during hematopoietic stem cell mobilization were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reaction (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). It should be noted that the majority of these occurred in patients also undergoing apheresis.
Outcome Measure Time Frame:
Primary Outcome Measure Time Frame: At baseline and at 8 hours post-Plerixafor (Mozobil) treatment
Secondary Outcome Measures Time Frame:
i.): Continuously for the first 30 minutes post-Plerixafor (Mozobil) treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment.
ii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment.
iii.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment.
iv.): For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment, at 1 week post-Plerixafor (Mozobil) treatment, and up to 1 year post treatment.
Primary Study Goals:
To determine whether Plerixafor (Mozobil) will mobilize CD117+ progenitor cells from the bone marrow in patients with chronic lung diseases on the lung transplant waiting list (versus normal controls). We will compare baseline counts of CD117+ cells with cell counts 8 hrs after Plerixafor to determine the efficacy of mobilization.
The primary results will be used to determine the number of rounds of apheresis that may be required to isolate sufficient cells for reinfusion at later timepoints in a future study.
Significance:
If the investigators can mobilize a sufficient number of autologous CD117+ cells, they will eventually re-infuse them at the time of transplant to determine whether we can abrogate acute rejection following human lung transplantation (future study). The investigators believe these are safer than allogeneic stem cells as there is no risk for graft versus host disease (GVHD) with autologous cells.
Hypothesis:
These experiments should demonstrate the effectiveness of CD117+ stem cell mobilization from the bone marrow to the peripheral blood (PB) via CXCR4 antagonism (Plerixafor) and whether end-stage lung disease affects the ability to mobilize stem cells. Additionally, these results will be used to mathematically extrapolate approximately how many rounds of peripheral blood apheresis will be required to attain adequate stem cell numbers for clinical infusion (10e7) for a future study.
Methods:
Experiments will involve taking blood from consented patients awaiting lung transplantation (as well as normal controls) prior to Plerixafor (Mozobil) treatment (240mcg/kg subcutaneously) and then 8 hours after treatment as in Table 1.
TABLE 1:
Patient Category PB baseline analysis Plerixafor (Mozobil) Rx PB analysis 8hrs post-Rx
Awaiting Tx (n=15, 5 chronic obstructive pulmonary disease (COPD), 5 Cystic Fibrosis (CF), and 5 Pulmonary Fibrosis (PF)) CD117 isolation/analysis by Flow Cytometry Yes - 240 mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry
Normal Control (n=5) CD117 isolation/analysis by Flow Cytometry Yes - 240mcg/kg CD117+ stem cell isolation/analysis by Flow Cytometry
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients on the Univ. of Colorado Lung Transplant Waiting List Age 18 to 70 years old Ability to sign and understand informed consent
- Patients 18 years or older up to age 70 on the University of Colorado Lung Transplant Waiting List and normal control subjects will be eligible for enrollment. Patients will include those with Chronic Obstructive Lung Disease, Pulmonary Fibrosis and Cystic Fibrosis
Normal control subjects = 5
Lung Transplant waitlist patients = 15 (5 each with COPD, PF or CF to determine whether disease affects mobilization potential)
Exclusion Criteria:
- Subject has already undergone lung transplantation.
- Subject has a known or suspected allergy to Plerixafor.
- Women of child-bearing age who are unwilling to use appropriate birth control to prevent becoming pregnant.
- Subjects who have received an investigational agent or device within 30 days of administration of the study agent. For the purposes of this trial, an investigational agent or device is any which is implemented under an Investigational New Drug Application (IND).
- Subjects with a history of Hepatitis B or C.
- Subjects with significant anemia (HCT < 35),thrombocytopenia (Plt count <100,000/cc), leukocytosis (WBC > 12,000/cc), or leucopenia (WBC < 5,000/cc).
- Subjects with splenomegaly.
- Subjects unable to comply with all protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Plerixafor (Mozobil) Control Arm
Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
|
Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
Other Names:
|
Experimental: Plerixafor (Mozobil) Experimental Arm
Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
|
Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of circulating CD117+ cells per milliliter (ml) of peripheral blood at baseline and following Plerixafor (Mozobil) treatment (change in peripheral blood CD117+ cells per ml).
Time Frame: At baseline and at 8 hours post-Plerixafor (Mozobil) treatment
|
At baseline and at 8 hours post-Plerixafor (Mozobil) treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of Plerixafor (Mozobil) related adverse events (AEs)
Time Frame: For 30 minutes after administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment.
|
For 30 minutes after administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment.
|
The number of patients with Plerixafor (Mozobil) related adverse events
Time Frame: For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment
|
For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment
|
The number of Plerixafor (Mozobil) related serious adverse events (SAEs).
Time Frame: For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment
|
For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment
|
The number of patients with Plerixafor (Mozobil) related serious adverse events (SAEs)
Time Frame: For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment
|
For the first 30 minutes post administration, at 1 week post-Plerixafor (Mozobil) treatment and up to 1 year post treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Todd Grazia, M.D., The University of Colorado Denver - Anschutz Medical Campus
Publications and helpful links
General Publications
- Blum A, Childs RW, Smith A, Patibandla S, Zalos G, Samsel L, McCoy JP, Calandra G, Csako G, Cannon RO 3rd. Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease. Cytotherapy. 2009;11(8):1016-9. doi: 10.3109/14653240903131640.
- Bonig H, Chudziak D, Priestley G, Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol. 2009 Mar;37(3):402-15.e1. doi: 10.1016/j.exphem.2008.10.017. Epub 2009 Jan 20.
- D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011 Mar;46(3):356-63. doi: 10.1038/bmt.2010.128. Epub 2010 May 31.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-0388
- 11BGF-31, Project #:2565477 (Other Grant/Funding Number: Colorado State BDEG Grant #: 11BGF-31, Project #:2565477)
- MAMO0811-1 (Other Identifier: Sanofi)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingIdiopathic Pulmonary Fibrosis | Pulmonary Disease | Pulmonary MedicineFrance
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Centre Hospitalier Universitaire de NiceRecruitingPulmonary Disease, Chronic Obstructive | Interstitial Pulmonary FibrosisFrance
-
Boehringer IngelheimNot yet recruitingIdiopathic Pulmonary Fibrosis | Progressive Pulmonary Fibrosis
Clinical Trials on Plerixafor mobilization of autologous CD117 stem cells
-
Hospital Universitario Dr. Jose E. GonzalezCompleted
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Losordo, Douglas, M.D.WithdrawnMyocardial Ischemia | Cardiovascular Disease | Congestive Heart FailureUnited States
-
The Mediterranean Institute for Transplantation...UnknownCongestive Heart FailureItaly
-
Instituto Mexicano del Seguro SocialCompletedMandibular Fractures
-
Losordo, Douglas, M.D.TerminatedMyocardial Ischemia | Cardiovascular Disease | Congestive Heart FailureUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); Food and Drug...Active, not recruiting
-
Mashhad University of Medical SciencesCompleted
-
University of JordanCompletedOsteoarthritis, Knee | Articular Cartilage Disorder of KneeJordan
-
Clínica Las Condes. LIT INNOVA CORFOUnknownSpinal Cord InjuryChile